{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Appendix C', \"Mc Donald's criteria for diagnosis of MS\", 'TABLE 4: The 2010 McDonald Criteria for Diagnosis of MS', 'Clinical Presentation', 'Additional Data Needed for MS Diagnosis', '>2 attacks; objective clinical', 'None', 'evidence of >2 lesions or objective', 'clinical evidence of 1 lesion with', 'reasonable historical', 'evidence of a prior attackb', '>2 attacks\"; objective clinical', 'Dissemination in space, demonstrated by:', 'evidence of 1 lesion', '>1 T2 lesion in at least 2 of 4 MS-typical regions of the CNS', '(periventricular, juxtacortical, infratentorial, or spinal cord): or', 'Await a further clinical attack implicating a different CNS site', '1 attack\"; objective clinical', 'Dissemination in time, demonstrated by:', 'evidence of >2 lesions', 'Simultaneous presence of asymptomatic gadolinium-enhancing', 'and nonenhancing lesions at any time; or', 'A new T2 and/or gadolinium-enhancing lesion(s) on follow-up', 'MRI, irrespective of its timing with reference to a baseline scan; or', 'Await a second clinical attack', '1 attack objective clinical', 'Dissemination in space and time, demonstrated by:', 'evidence of 1 lesion', 'For DIS:', '(clinically isolated syndrome)', '>1 T2 lesion in at least 2 of 4 MS-typical regions of the CNS', '(periventricular, juxtacortical, infratentorial, or spinal cord)d; or', 'Await a second clinical attack implicating a different CNS site; and', 'For DIT:', 'Simultaneous presence of asymptomatic gadolinium-enhancing', 'and nonenhancing lesions at any time; or', 'A new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI,', 'irrespective of its timing with reference to a baseline scan; or', 'Await a second clinical attack', 'Insidious neurological progression', '1 year of disease progression (retrospectively or prospectively', 'suggestive of MS (PPMS)', 'determined) plus 2 of 3 of the following criteriad:', '1. Evidence for DIS in the brain based on >1 T2 lesions in the', 'MS-characteristic (periventricular, juxtacortical, or infratentorial) regions', '2. Evidence for DIS in the spinal cord based on >2 T2', 'lesions in the cord', '3. Positive CSF (isoelectric focusing evidence of oligoclonal bands', 'and/or elevated IgG index)', 'If the Criteria are fulfilled and there is no better explanation for the clinical presentation, the diagnosis is \"MS\"; if suspicious, but', 'the Criteria are not completely met, the diagnosis is \"possible MS\"; if another diagnosis arises during the evaluation that better', 'explains the clinical presentation, then the diagnosis is \"not MS.\"', '\"An attack (relapse; exacerbation) is defined as patient-reported or objectively observed events typical of an acute inflammatory', 'demyelinating event in the CNS, current or historical, with duration of at least 24 hours, in the absence of fever or infection. It', 'should be documented by contemporaneous neurological examination, but some historical events with symptoms and evolution', 'characteristic for MS, but for which no objective neurological findings are documented, can provide reasonable evidence of a prior', 'demyelinating event. Reports of paroxysmal symptoms (historical or current) should, however, consist of multiple episodes occur-', 'ring over not less than 24 hours. Before a definite diagnosis of MS can be made, at least 1 attack must be corroborated by findings', 'on neurological examination, visual evoked potential response in patients reporting prior visual disturbance, or MRI consistent', 'with demyelination in the area of the CNS implicated in the historical report of neurological symptoms.', 'blinical diagnosis based on objective clinical findings for 2 attacks is most secure. Reasonable historical evidence for 1 past attack,', 'in the absence of documented objective neurological findings, can include historical events with symptoms and evolution character-', 'istics for a prior inflammatory demyelinating event; at least 1 attack, however, must be supported by objective findings.', '\"No', 'additional tests are required. However, it is desirable that any diagnosis of MS be made with access to imaging based on these', 'Criteria. If imaging or other tests (for instance, CSF) are undertaken and are negative, extreme caution needs to be taken before', 'making a diagnosis of MS, and alternative diagnoses must be considered. There must be no better explanation for the clinical pre-', 'sentation, and objective evidence must be present to support a diagnosis of MS.', 'Gadolinium-enhancing lesions are not required; symptomatic lesions are excluded from consideration in subjects with brainstem', 'or spinal cord syndromes.', 'MS = multiple sclerosis; CNS = central nervous system; MRI = magnetic resonance imaging; DIS = dissemination in space; DIT =', 'dissemination in time; PPMS = primary progressive multiple sclerosis; CSF = cerebrospinal fluid; IgG = immunoglobulin G.', 'Property of the Sanofi Group - strictly confidential', 'Page 113', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Appendix D', \"Kurtzke's Functional Systems and Expanded Disability Status Scale\", 'in Multiple Sclerosis', 'neurostatus scoring', 'Definitions for a standardised, quantified neurological examination', \"and assessment of Kurtzke's Functional Systems and Expanded\", 'Disability Status Scale in Multiple Sclerosis', 'Slightly modified from J.F. Kurtzke, Neurology 1983:33,1444-52', '\u00a92011 Ludwig Kappos, MD, Neurology, University Hospital Basel,', '4031 Basel, Switzerland; Version 04/10.2', 'Property of the Sanofi Group - strictly confidential', 'Page 114', 'VV-CLIN-0254406: 5.0']\n\n###\n\n", "completion": "END"}